Human apolipoprotein A1 (Apo-A1) ELISA Kit

Code CSB-E08103h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name apolipoprotein A-I
Alternative Names Apo-AI ELISA Kit; ApoA I ELISA Kit; ApoA-I ELISA Kit; APOA1 ELISA Kit; APOA1_HUMAN ELISA Kit; Apolipoprotein A-I(1-242) ELISA Kit; Apolipoprotein A1 ELISA Kit; Apolipoprotein AI ELISA Kit; Apolipoprotein of high density lipoprotein ELISA Kit; ApolipoproteinAI ELISA Kit; Brp14 ELISA Kit; high density lipoprotein uptake ELISA Kit; Ltw1 ELISA Kit; Lvtw1 ELISA Kit; MGC117399 ELISA Kit; Sep1 ELISA Kit; Sep2 ELISA Kit
Abbreviation APOA1
Uniprot No. P02647
Species Homo sapiens (Human)
Sample Types serum, plasma, cell culture supernates, saliva, urine
Detection Range 1.4 ng/mL-1000 ng/mL
Sensitivity 0.7 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cardiovascular
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
To assess the linearity of the assay, samples were spiked with high concentrations of human Apo-A1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:2000 Average % 88  
Range % 84-92  
1:4000 Average % 96  
Range % 92-102  
1:8000 Average % 95  
Range % 89-100  
1:16000 Average % 92  
Range % 89-96  
The recovery of human Apo-A1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 94 89-98  
EDTA plasma (n=4) 96 91-101  
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
1000 1.879 1.903 1.891 1.728  
500 1.592 1.612 1.602 1.439  
250 1.304 1.311 1.308 1.145  
125 0.955 0.968 0.962 0.799  
62.5 0.743 0.757 0.750 0.587  
31.2 0.562 0.572 0.567 0.404  
15.6 0.374 0.376 0.375 0.212  
0 0.161 0.165 0.163    
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Target Data

Function Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
Gene References into Functions
  1. Plasma apoA-I proteolysis is augmented in aortic valve stenosis and cathepsin S exerts the most deleterious effects on apoA-I integrity in humans. PMID: 29915952
  2. This study explores how the high-density lipoproteins lipid composition influences amyloid deposition by apoA-I and related proteins. PMID: 27768903
  3. Site-specific, covalent modifications of apoA-I (lysines or arginines) led to altered protein structure, reduced lipid binding capability and a reduced ability to catalyze cholesterol efflux from macrophages, partly in a modification-specific manner. PMID: 29802959
  4. assessing the quality of ApoA1 and, in turn, that of HDL in circulating blood can serve as an early diagnostic tool for cardiovascular diseases (CVDs). In this study, we developed monoclonal antibodies (mAbs) specific to modified ApoA1 with its tyrosine residue at the 166th position nitrated to 3-nitrotyrosine PMID: 30132720
  5. Vitreous levels of APOA1 and RBP4 in human rhegmatogenous retinal detachment associated with choroidal detachment reflects the severity of disease. PMID: 29618920
  6. The objective of this study was to evaluate whether apolipoprotein gene polymorphisms confer susceptibility to osteonecrosis of the femoral head. PMID: 30119683
  7. Case Report: recurrence of non-familial hereditary apolipoprotein A-I amyloidosis in Japanese transplant recipient with two novel APOA1 mutations. PMID: 29968409
  8. TNFalpha differently regulated the levels of PPARalpha, LXRalpha, and LXRbeta binding to the apoA-I gene promoter in THP-1 cells. Obtained results suggest a novel tissue-specific mechanism of the TNFalpha-mediated regulation of apoA-I gene in monocytes and macrophages and show that endogenous ApoA-I might be positively regulated in macrophage during inflammation. PMID: 29442267
  9. An increased apo B/apo A1 ratio was independently associated with all-cause mortality and cardiovascular events in peritoneal dialysis patients. PMID: 29776362
  10. he present study reveals that there may be a racial/ethnic- and/or gender-specific association between the APOA1 rs964184 SNP and serum lipid parameters in our study populations PMID: 29747660
  11. In this study the APOA1 (rs670) gene showed important effects on body weight, adiposity, LDL-cholesterol levels and insulin resistance after 12weeks of the dietary intervention PMID: 29859275
  12. Residues 26-43 of one APOA1 in the smaller particle form a hinge on the disc edge, which displaces the C-terminal domain of the other APOA1 to the phospholipid surface PMID: 29712830
  13. H1 receptor signaling is a novel pathway of apo A1 gene expression PMID: 29378195
  14. genetic polymorphisms of ApoA1 rs5070 A/G may play a role in the susceptibility to large artery atherosclerosis among male diabetic patients. PMID: 28238629
  15. Single Nucleotide Polymorphism in APOA1 gene is associated with dyslipidemia. PMID: 29758034
  16. rs670, rs2854116, and rs662799 single nucleotide polymorphisms of the APOA1-C3-A5 cluster are associated with ischemic stroke in the northern Chinese Han population. PMID: 28635360
  17. Higher levels of TG, LPO (P<0.0001), nonHDL/HDL and ApoB/ApoA1 (P<0.001, 0.05, respectively), and lower levels of HDL-c, ApoA1, and PON1 (P<0.0001) were observed in T2DM subjects than in controls. PMID: 29626583
  18. Data suggest that N(epsilon)-(carboxyethyl)lysine (CEL) modification of ApoA1 is up-regulated in serum from patients with Alzheimer's disease (AD); CEL-ApoA1 is a kind of advanced glycation end product; this leads to up-regulation of anti-CEL-ApoA1 IgM in early disease. Both CEL and anti-CEL IgM may serve as AD biomarkers. PMID: 29680706
  19. The osteonecrosis of the femoral head patients had higher A/A genotype proportions on the apolipoprotein A1 gene 75bp, compared to the control group, while the G/A genotype frequency was lower in the affected patients. This suggests that the G/A mutation on Apo A1 promoter might be one of the predisposing factors for osteonecrosis of the femoral head. PMID: 28770971
  20. Independent evidence indicated LpAI:A-II has a diameter 20% smaller than LpAI, consistent with a model having two apoA-I and one apoA-II PMID: 27526664
  21. ApoA1 combined with 9alpha,11ss-PGF2 represents a useful composite biomarker of anaphylaxis, achieving superior diagnostic power over either factor alone. PMID: 28378321
  22. Low-dose lipid-free apoA-I treatment in atherosclerotic mice preserves and restores collecting lymphatic vessels function by direct and indirect mechanisms. PMID: 28939717
  23. APOA1 gene may be associated with low HDL-cholesterol disease in the pastoral area of northwest China. PMID: 28969676
  24. Our results strongly suggest that plasma concentrations of EPA and DHA influence aspirin effects on lipid mediators of CVD event risk where their concentrations are most beneficial when moderate, not high or low. These effects on HDL-C cholesterol and apoA-I exchange are novel. PMID: 29031392
  25. A multidisciplinary approach, including circular dichroism, dynamic light scattering, spectrofluorometric and atomic force microscopy analyses, monitored the effect of target cells on the conformation and fibrillogenic pathway of the two AApoAI amyloidogenic variants AApoAI(L75P) and AApoAI(L174S). Specific cell milieus selectively affect conformation, aggregation propensity and fibrillogenesis of these variants. PMID: 29174954
  26. we demonstrated a 21.6% decrease in serum ApoA-I in FA patients compared with non-affected controls PMID: 29447225
  27. Smaller apolipoprotein(a) isoform size and increased lipoprotein(a) concentration are independent and causal risk factors for coronary heart disease. PMID: 28408323
  28. In conclusion, decreasing levels of apolipoproteins B and A1 were associated with increased risk of venous thrombosis. PMID: 28540474
  29. Serum ApoA-I level was negatively correlated with the formation of vocal fold polyps, suggesting ApoA-I may reduce the risk of vocal fold polyps. PMID: 27816355
  30. data indicate that low apoA1 levels are an independent predictor of the poor clinical outcomes in invasive ductal carcinoma patients. PMID: 28595037
  31. Data suggest that Apolipoprotein A1 (ApoA-1) might be a promising therapeutic target to reduce recurrence and metastasis for hepatocellular carcinoma (HCC) patients after resection. PMID: 27683106
  32. The generated structures provide evidence for the discoidal, antiparallel arrangement of apoA-I in nascent HDL, and propose two preferred conformations of the flexible N-termini PMID: 28754383
  33. identified that apolipoprotein-A1 and haptoglobin had significant predictive values for the prediction of recovery at 12 weeks in DILI, enabling the construction of a new prognostic panel, the DILI-ActiTest, which needs to be independently validated PMID: 29287080
  34. ApoA1 is associated with neurite outgrowth after mechanical injury by mediating polymerisation of actin and restricting inflammatory responses after injury which are deleterious to healing. PMID: 27100352
  35. A retractable lid in lecithin:cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-I PMID: 29030428
  36. Lower ApoA1 improves the risk prediction of new type 2 diabetes PMID: 28502492
  37. Following ETC-216 administration to normal human volunteers, an initial dose-dependent HDL-C elevation was observed. Thereafter, subjects transiently acquired a lipoprotein profile similar to that of AIM carriers, including reduced HDL-C and mild hypertriglyceridemia. PMID: 27155060
  38. The different anti-inflammatory mechanisms of the ApoA-I cysteine mutants might be associated with the regulation of ATF3 level. PMID: 28093456
  39. Anti-apoA-1 IgG are independent predictors of nonfatal incident coronary artery disease in the general population. The strength of this association is dependent on a functional polymorphism of the CD14 receptor gene, a finding suggesting a gene-autoantibody interaction for the development of CAD. PMID: 29074586
  40. In vitro proteolysis of the apoA-I-Cy5.5 probe by a variety of proteases including serine, cysteine, and metalloproteases resulted in an up to 11-fold increase in fluorescence, allowing for quantification of apolipoprotein A-I proteolytic degradation. PMID: 28167355
  41. Using atomic force microscopy, detail the ring-shaped coarse structure, and the three detailed structures of apoA-I directly derived from spherical HDL through NP-40-induced lipid depletion. PMID: 28279834
  42. These data suggest that high doses of insulin downregulate apoA-I gene expression in HepG2 cells through redistribution of FOXO1/LXRbeta complex, FOXA2, and LXRalpha on hepatic enhancer of apoA-I gene. PMID: 27404023
  43. Our findings suggest that serum ApoA-I level should be evaluated as a predictor of survival in patients with esophageal squamous cell carcinoma PMID: 27444612
  44. Inflammatory markers modify the risk of recurrent coronary events associated with apolipoprotein A-I in postinfarction patients PMID: 28391888
  45. Serum Apo-A1 was significantly lower in term SGA newborns compared to control term newborns. PMID: 28304324
  46. This study showed that the predictive value of apolipoprotein B/A-I ratio for coronary artery calcification may differ according to kidney function. PMID: 28957410
  47. Findings suggest that the ABCG1-mediated efflux of cholesterol, but not of 7-ketocholesterol, shows specificity for structural domains of apoA-I bound to reconstituted HDL. Although the mid region alone of apoA-I associated to rHDL can promote ABCG1-mediated cholesterol efflux, deletion of carboxyl-terminal region 185-243 from full-length apoA-I diminishes ABCG1-mediated cholesterol efflux. PMID: 23826352
  48. Low APOA1 expression is associated with coronary artery disease severity. PMID: 28038449
  49. Data suggest that activation of SR-BI by APOAI down-regulates sphingosine 1-phosphate/S1PR2-mediated inflammation in vascular endothelial cells by activating the PI3K/Akt signaling pathway; oxidized-LDL does the opposite. (APOA1 = apolipoprotein A-I; SR-BI/SCARB1 = scavenger receptor class B type I; S1PR2 = sphingosine 1-phosphate receptor 2; PI3K = phosphatidylinositol 3-kinase; Akt = proto-oncogene c-akt) PMID: 28181168
  50. The minor alleles of rs662799 (APOA5) and rs5072 (APOA1) modulate TG levels in Mexican children PMID: 27171122
  51. Objective of this study was to understand their structural and functional role by generating domain swapped chimeras: apoE3-N-terminal/apoAI-C-terminal and apoAI-N-terminal/apoE-C-terminal. Results indicate that the functional attributes of apoAI and apoE3 can be conferred on each other and that N-terminal-C-terminal domain interactions significantly modulate their structure and function. PMID: 28644829
  52. These data demonstrate that complex of PPARgamma with GW1929 is a negative regulator involved in the control of ApoA-I expression and secretion in human hepatocyte- and enterocyte-like cells PMID: 26813964
  53. Human apoA-I was overexpressed by transfection in BEL-7402 hepatocytes and by an adenoviral vector in C57BL/6J mice fed a methionine choline-deficient diet. The overexpression of apoA-I in both models resulted in decreased reactive oxygen species and lipid peroxidation levels, as well as a reduced MAPK phosphorylation and decreased expression levels of c-Fos and COX-2. PMID: 25451254
  54. The H10B sequence repeat of lipid-free human apoA-I is vital in HDL formation. PMID: 27317763
  55. Our results assign a novel role for 4F(apoA-I mimetic peptide ) as a modulator of the TICE pathway and suggest that the anti-inflammatory functions of 4F may be a partial consequence of the codependent intestinal transport of both 4F and cholesterol. PMID: 27199144
  56. these data highlight a key role of the P2Y1/PI3Kbeta axis in endothelial cell proliferation downstream of ecto-F1-ATPase activation by apoA-I. Pharmacological targeting of this pathway could represent a promising approach to enhance vascular endothelial protection. PMID: 28578353
  57. This study demonstrated for the first time that apoA-1, as a blood marker, can predict microstructural changes in white matter regions in PD patients with undisturbed cognition and mild motor disability. PMID: 28168521
  58. he lead variant was the rs1558861 [1.99 (1.73-2.30); p = 7.37 x 10(-22) ], residing on chromosome (chr) 11 at the apolipoprotein A-I/A-5 (APOA1/APOA5) locus PMID: 27599772
  59. We found inverse independent correlations between metabolic clearance rate of insulin (MCRI) and hepatic lipase (P = 0.0004), insulin secretion (P = 0.0002), alanine aminotransferase (P = 0.0045), total fat mass (P = 0.014), and diabetes (P = 0.03). MCRI and apolipoprotein A-I exhibited a positive independent correlation (P = 0.035). PMID: 27846285
  60. Anacetrapib treatment increases HDL apoA-I and CETP levels by decreasing the fractional clearance rate of each protein PMID: 26966279
  61. Our findings confirm a causal association of APOA1 with gout. PMID: 27094595
  62. Epidemiological and functional studies underline a prognostic value of ApoA1 self-antibodies for several cardiovascular diseases. Review. PMID: 27183204
  63. ApoA-I is inversely associated with insulin resistance in patients with impaired glucose tolerance, and low apoA-I is an independent risk factor for impaired glucose tolerance (IGT). These results indicate that apoA-I plays an important role in regulating insulin sensitivity and glucose metabolism in patients with IGT. PMID: 28372564
  64. Results suggest that Apo-A1 plays a protective role in inflammatory reaction and might be a predictor for severity of gout and therapeutic target PMID: 28445313
  65. the initial rapid aggregation of LDL(-) is apparently counterbalanced by the stabilizing effects of minor proteins such as apoA-I and apoJ. These results help identify key determinants for LDL aggregation, fusion and coalescence into lipid droplets in vivo. PMID: 27233433
  66. structure and function of ApoA-I PMID: 27790714
  67. Apo A-I and paraoxonase-1 levels may be clinically useful for ischemic stroke diagnosis and for differentiating between ischemic and hemorrhagic strokes. PMID: 26994915
  68. Compared with healthy controls, preeclamptic patients had significantly lower Apo A-1 levels (167.07mg/dl+/-14.61mg/dl vs. 244.37mg/dl+/-20.84mg/dl, p<0.001), higher Apo B-100/Apo A-1 ratio (0.63+/-0.07 vs. 0.42+/-0.05, p<0.001), but similar Apo B-100 levels (104.84mg/dl+/-7.05mg/dl vs. 102.39mg/dl+/-8.08mg/dl, p=0.118). PMID: 27155339
  69. ApoM/HDL-C and apoM/apoA1 ratios could be used as indicators for identification of DN from healthy people and from T2DM patients. PMID: 28073663
  70. Higher level of some risk factors like PAB values, apoB/A1 ratio concentration, and lipid profiles is able to involve in the prognostic pathological consequences in patients with beta-thalassemia major. Even so, they contribute toward the gradual development of CVD. PMID: 25913481
  71. APOA1 SNPs (rs670, rs5069, and rs2070665) are not associated with dyslipidemia in the Kazakh population of China. PMID: 27173266
  72. the data described the region around residue 217 in the C-terminal domain of apoA-I as the most sensitive reporter of the crowding-induced self-association of apoA-I. The implications of this behavior to in vivo functionality are discussed. PMID: 27122373
  73. ApoA1 is increasingly expressed and secreted as a delayed response to neuronal injury, and this is a self-protecting mechanism of the injured system. PMID: 27734225
  74. A novel APOA1 mutation in hereditary apolipoprotein A-I amyloidosis PMID: 27240838
  75. The genotype frequency of APOA1 (rs5069, rs670) in a cohort of patients with CAA-associated intracerebral hemorrhage was compared with hypertension-associated ICH, Alzheimer disease, and controls. The APOA1 genotypes were not different among groups. apoA1 may act as a physiological transporter of Abeta(1-40). PMID: 26661731
  76. RVX-208 raises ApoA-I/HDL and represses pro-inflammatory, pro-atherosclerotic and pro-thrombotic pathways that can contribute to cardiovascular disease risk. PMID: 26868508
  77. Epigenetic silencing of ApoA1 gene expression by CpG island DNA hypermethylation induced by Hepatitis B virus. PMID: 27015844
  78. protein(s) in the homogenate interact with HDL protein(s), leading to release of Apo A1 from the HDL particle, a process that was associated with an increase in HDL diameter and with impaired HDL anti-oxidant activity. PMID: 26662883
  79. Data indicate that serum apolipoproteins ApoB, ApoA-1 and ApoB/A-1 ratio levels are independently associated with coronary heart disease (CHD) risk in Korean men. PMID: 26118305
  80. Expression of ApoA-1 and ApoC-III in SCLC was significantly different, compared with that in NSCLC and normal lung tissues, and was correlated with recurrence of SCLC. PMID: 26996551
  81. Static and dynamic light scattering were employed to determine simultaneously the average relative molecular mass, Mr, and the average hydrodynamic radius, Rh, of protein molecules. The new method was applied to the association-dissociation equilibrium of apolipoprotein A-1 (Apo A-1) and its thermal unfolding. PMID: 26819136
  82. serum APOA1 levels were associated with cognitive decline and brain atrophy independent of amyloid-beta deposition and vascular burden in patients with amnestic mild cognitive impairment PMID: 26238231
  83. level of ApoA-I at diagnosis is a novel independent prognostic marker that could complement clinical staging for risk definition in non-metastatic nasopharyngeal carcinoma PMID: 26503474
  84. Increased plasma homocysteine(Hcy) levels were associated with decreased apoAI levels in healthy people, and the inhibition of apoAI synthesis might be a mechanism through which Hcy is linked with the development of atherosclerosis in hyperHcy subjects. PMID: 26758372
  85. High urine APOA1 expression is associated with clear cell renal cell carcinoma. PMID: 26420021
  86. The incidence of allele (-75)A was 22.5%, of allele (+83)T - 7.3%. Association of allele (-75) A with high blood cholesterol level was revealed. PMID: 26621275
  87. ApoB/ApoA1 SNPs are associated with alcohol-induced alcohol-induced osteonecrosis of femoral head in the Han Chinese population. PMID: 26617857
  88. phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene PMID: 26687706
  89. natural apoA-I mutations L141RPisa and L159RFIN affect the biogenesis and the functionality of HDL in vivo and predispose to diet-induced atherosclerosis in the absence of any other genetic defect PMID: 26363436
  90. ApoA1 and ApoA2 were independently associated with cognitive impairment. PMID: 26682220
  91. reduced ApoA1 level and increased ApoB level and ApoB/A1 ratio are risk factors for a first ischemic but not hemorrhagic stroke--{REVIEW} PMID: 26363640
  92. Data show although no any significant differences between patient groups and lean subjects of proteins SYT4, BAG3, APOA1, and VAV3, except for VGF protein, there was a trend between the expression of these four genes and their protein levels. PMID: 26337083
  93. The results of this study confirmed the association of lower plasma ApoA1 levels in earlier age of Parkinson's disease. PMID: 26207725
  94. Patients with renal cancer had a significantly higher frequency of APOA1 -75 AA genotype. PMID: 26537097
  95. Low levels of APOA1, APOC3, and APOA4 are associated with risk of Alzheimer disease. PMID: 26491253
  96. The ratio of serum apoB100/apoAI was independently and positively associated with the tertile of the Gensini scores for the severity of coronary heart disease. PMID: 26582246
  97. Together, the results suggest that reduced protection of the major amyloid "hot spot", combined with the structural integrity of the native helix bundle conformation, shifts the balance from protein clearance to beta-aggregation. PMID: 26562506
  98. ApoA-I requires lipid to stabilize VWF under shear. PMID: 26552698
  99. Identify C-terminal cleavage of apoA-I by human mast cell chymase as a novel mechanism leading to loss of its anti-inflammatory functions. PMID: 26681753
  100. The administration of FAMP promoted ABCA1-dependent efflux ex vivo, HDL turnover in vivo, and macrophage RCT in vivo despite reduced plasma HDL-C levels. FAMP might have atheroprotective potential. PMID: 26005953

Show More

Hide All

Involvement in disease High density lipoprotein deficiency 2 (HDLD2); High density lipoprotein deficiency 1 (HDLD1); Amyloidosis 8 (AMYL8)
Subcellular Location Secreted
Protein Families Apolipoprotein A1/A4/E family
Tissue Specificity Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b
Database Links

HGNC: 600

OMIM: 105200

KEGG: hsa:335

STRING: 9606.ENSP00000236850

UniGene: Hs.93194

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1